secwatch.observer — SEC 8-K summary
======================================

Issuer:     International Stem Cell CORP (ISCO)
CIK:        0001355790
Form:       8-K
Filed at:   2026-07-16T00:11:52+00:00
Accession:  0001683168-26-005555
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ISCO agrees to sell Lifeline Cell Technology to ATCC for $25M in cash
---------------------------------------------------------------------

- Purchase price $25M, subject to net working capital, cash, and debt adjustments; closing expected Q3 2026.
- Seller must obtain stockholder consent from requisite holders; support agreements already signed for >50% voting power.
- Indemnity escrow of $2.5M and adjustment escrow of $100K; post-closing adjustment process with 90-day review.
- Transition services agreement to be effective at closing; non-solicitation and non-compete covenants for 5 years post-closing.
- LCT develops and sells primary human cells, stem cells, and cell culture media for scientific research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1355790/000168316826005555/0001683168-26-005555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1355790/000168316826005555/intlstemcell_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-005555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer